Home › Compare › BPC-157 vs Larazotide
BPC-157 vs Larazotide
BPC-157 and Larazotide are both healing & recovery peptides, which is why they get recommended interchangeably — but they are different compounds with different origins. The table below sets out the differences. We give no dosing guidance.
Side by side, in plain English — what each one is, where they overlap and where they genuinely differ.
BPC-157Healing & Recovery
LarazotideHealing & RecoveryAt a glance
| BPC-157 | Larazotide | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Typical route | SubQ | Oral |
| Shelf life once mixed | ~30 days | ~30 days |
| Commonly reported effects | Accelerated tissue healing Reduced inflammation Improved gut health Joint pain relief | Reduced intestinal permeability Symptom relief in celiac |
| Reported considerations | Mild injection site irritation Rare fatigue | Mild GI upset |
The differences that actually matter
Both are classed as Healing & Recovery peptides, so they get compared constantly and are often researched for overlapping reasons.
Route of administration differs — BPC-157 is typically subq, Larazotide is typically oral. That alone changes how convenient each one is to keep up with.
Where they overlap: reduced inflammation, joint pain relief.
Reported mainly for BPC-157: accelerated tissue healing, improved gut health.
What BPC-157 is
BPC-157 is a stable gastric pentadecapeptide, a sequence of 15 amino acids derived from human gastric juice. Its mechanism of action is complex and multifactorial, not directly targeting a single receptor but rather modulating several physiological pathways involved in tissue repair and protection. Research suggests it influences angiogenesis, the formation of new blood vessels, by interacting with growth factors such as VEGF and FGF-2. It also appears to modulate the nitric oxide system, promoting endothelial nitr
What Larazotide is
Larazotide is a synthetic octapeptide that functions primarily as an antagonist of zonulin, a protein involved in regulating the permeability of tight junctions in the intestinal epithelium. By binding to and inhibiting zonulin's activity, Larazotide helps to stabilize and strengthen these cellular junctions. This action reduces paracellular permeability, often described as "intestinal hyperpermeability" or "leaky gut," which can allow unwanted substances to cross the gut barrier and trigger immune responses. In co
How to compare them for yourself
Anecdotes online are noisy because nobody is measuring the same thing. The only comparison that means anything is your own: log each entry with a timestamp, keep the vial ledger honest so you know what you actually got through, pick two or three metrics before you start, and look at the trend after several weeks rather than day to day.
Peptide Wizard does that part for you — BPC-157 and Larazotide are both in the built-in reference library with a 3D vial, and your history, vial ledger and cost per entry stay private on your device.
FAQ
What is the difference between BPC-157 and Larazotide?
Both are classed as Healing & Recovery peptides, so they get compared constantly and are often researched for overlapping reasons.
Can you log BPC-157 and Larazotide in the same period?
Plenty of people record more than one peptide at a time. Peptide Wizard keeps a separate vial ledger and entry history for each, so you can see exactly what overlapped and when — it does not recommend combinations or doses.
Which is better, BPC-157 or Larazotide?
There isn't a universal answer — reported responses vary a lot between individuals, which is why your own log is more informative than anyone else's anecdote. Track one variable at a time and compare your own metrics over several weeks.
Is this medical advice?
No. This page is educational reference material only. It contains no dosing guidance. Speak to a qualified healthcare professional before making any decisions.
See all peptide comparisons →
Educational reference only. This page contains no dosing guidance and is not medical advice.